CHOLESTYRAMINE LIGHT
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- CHOLESTYRAMINE LIGHT
- Generic name
- CHOLESTYRAMINE LIGHT
- Manufacturer
- EPIC PHARMA, LLC
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 00990dec-7618-4cc8-9387-48c2cea8df1c
- SPL ID
- d1aa04ed-c076-4f53-a173-e8951360a1ea
- Version
- 2
- Effective date
- 2026-06-15
- Source export date
- 2026-09-28
- Source partition
- 3
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0003-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-09-28/fd09911bd1bc81f7f2faeb048e63855fe224e494376ae919a0035190e315c050/drug-label-0003-of-0014.json.zip
- Source manifest SHA-256
- cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
- Import run
- 20260929T050834Z
- Imported at
- 2026-09-29 05:19:22
| Harmonized routes |
|---|
| ORAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | ANDA | 074558 | derived:openfda.application_number |
| application number | ANDA074558 | openfda.application_number | |
| brand name | CHOLESTYRAMINE LIGHT | openfda.brand_name | |
| generic name | CHOLESTYRAMINE LIGHT | openfda.generic_name | |
| manufacturer name | EPIC PHARMA, LLC | openfda.manufacturer_name | |
| ndc | package | 42806-269-98 | openfda.package_ndc |
| ndc | product | 42806-269 | openfda.product_ndc |
| ndc11 | package | 42806026998 | derived:openfda.package_ndc |
| rxcui | 1801279 | openfda.rxcui | |
| spl id | d1aa04ed-c076-4f53-a173-e8951360a1ea | id | |
| spl set id | 00990dec-7618-4cc8-9387-48c2cea8df1c | set_id | |
| unii | 4B33BGI082 | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNINGS PHENYLKETONURICS: CHOLESTYRAMINE FOR ORAL SUSPENSION, USP LIGHT POWDER CONTAINS 22.4 mg PHENYLALANINE PER 5.7 GRAM DOSE.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS The most common adverse reaction is constipation. When used as a cholesterol-lowering agent predisposing factors for most complaints of constipation are high dose and increased age (more than 60 years old). Most instances of constipation are mild, transient and controlled with conventional therapy. Some patients require a temporary decrease in dosage or discontinuation of therapy. Less Frequent Adverse Reactions - Abdominal discomfort and/or pain, flatulence, nausea, vomiting, diarrhea, eructation, anorexia, steatorrhea, bleeding tendencies due to hypoprothrombinemia (Vitamin K deficiency) as well as Vitamin A (one case of night blindness reported) and D deficiencies, hyperchloremic acidosis in children, osteoporosis, rash and irritation of the skin, tongue and perianal area. Rare reports of intestinal obstruction, including two deaths, have been reported in pediatric patients. Occasional calcified material has been observed in the biliary tree, including calcification of the gallbladder, in patients to whom cholestyramine resin has been given. However, this may be a manifestation of the liver disease and not drug related. One patient experienced biliary colic on each of three occasions on which he took a cholestyramine for oral suspension product. One patient diagnosed as acute abdominal symptom complex was found to have a “pasty mass” in the transverse colon on x-ray. Other events (not necessarily drug related) reported in patients taking cholestyramine resin include: Gastrointestinal GI-rectal bleeding, black stools, hemorrhoidal bleeding, bleeding from known duodenal ulcer, dysphagia, hiccups, ulcer attack, sour taste, pancreatitis, rectal pain, diverticulitis. Laboratory Test Changes Liver function abnormalities. Hematologic Prolonged prothrombin time, ecchymosis, anemia. Hypersensitivity Urticaria, asthma, wheezing, shortness of breath. Musculoskeletal Backache, muscle and joint pains, arthritis. Neurologic Headache, anxiety, vertigo, dizziness, fatigue, tinnitus, syncope, drowsiness, femoral nerve pain, paresthesia. Eye Uveitis. Renal Hematuria, dysuria, burnt odor to urine, diuresis.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.